VHH EW
An anti-RBD (SARS-CoV-2 Spike) biparatopic nanobody.
General information
VHH EW is a biparatopic fusion nanobody derived from VHH E (C-terminus) and VHH W (N-terminus), which are specific for SARS-CoV-2 Spike RBD and bind non-overlapping epitopes. The two paratopes likely bind RBD epitopes on different subunits of the trimeric Spike complex. The parent monovalent nanobodies were identified using the phage display technique and originally produced by immune cells of a llama and an alpaca immunized with SARS-CoV-2 Spike RBD and inactivated SARS-CoV-2 virus. VHH EW is more potent in pseudovirus neutralization than VHH E or VHH W. The biparatopic nanobody likely induces conformational changes to Spike (Koenig et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape
Spike protein ACE2 Cryo-EM Crystallization Biophysical assay In vitro Mechanism Antibody |
llama and alpaca immune cells (source); in vitro biophysical assay; cryo-EM; crystallization; Vero E6 cells; Caco-2 cells; HEK293T cells; hACE2-HEK293T cells; SARS-CoV-2 Spike Δ18 pseudovirus; SARS-CoV-2 isolate SARS-CoV-2/human/Germany/Heinsberg-01/2020 | 41.85 | In vitro, the biparatopic nanobody inhibited SARS-CoV-2 Spike pseudotyped virus infection with an IC50 of 1.8 nM. |
Feb/12/2021 |
